Innovus Pharma Reports Quarterly Revenue For The First Quarter 2017 Of $2.2 Million

SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB: INNV), today announced first quarter 2017 net revenue of $2.2 million compared to $0.2 million in net revenues for the same period in 2016.

“We have not only seen an increase in our net revenue from the most recent fourth quarter 2016 but our operating loss and cash used in operations has improved as we continue to work to achieve our goal of profitability,” stated Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “With the exciting news stemming from the commercial supply agreement we entered into with our new partner for FlutiCare™ in May 2017 and the recent completion of our registered public equity offering in March 2017, we believe we are well on our way to having the necessary resources to assist us in executing our goals of the expected launch of FlutiCare™ in the fourth quarter of 2017, the continued expansion of our product lines and achieving profitability.”

Financial highlights for the three months ended March 31, 2017 included:

Back to news